The Effect of Plasma Triglyceride-Lowering Therapy on the Evolution of Organ Function in Early Hypertriglyceridemia-Induced Acute Pancreatitis Patients With Worrisome Features (PERFORM Study): Rationale and Design of a Multicenter, Prospective, Observational, Cohort Study



Cao, Longxiang, Zhou, Jing, Chen, Mingzhi, Chen, Tao ORCID: 0000-0002-5489-6450, Liu, Man, Mao, Wenjian, Lin, Jiyan, Hong, Donghuang, Yao, Weijie, Sun, Yi
et al (show 11 more authors) (2021) The Effect of Plasma Triglyceride-Lowering Therapy on the Evolution of Organ Function in Early Hypertriglyceridemia-Induced Acute Pancreatitis Patients With Worrisome Features (PERFORM Study): Rationale and Design of a Multicenter, Prospective, Observational, Cohort Study. FRONTIERS IN MEDICINE, 8. 756337-.

[img] Text
Manuscript ENFORM.pdf - Author Accepted Manuscript

Download (443kB) | Preview

Abstract

<b>Background:</b> Acute pancreatitis (AP) is a potentially life-threatening inflammatory disease with multiple etiologies. The prevalence of hypertriglyceridemia-induced acute pancreatitis (HTG-AP) has been increasing in recent years. It is reported that early triglyceride (TG) levels were associated with the severity of the disease, and TG- lowering therapies, including medical treatment and blood purification, may impact the clinical outcomes. However, there is no consensus regarding the optimal TG-lowering therapy, and clinical practice varies greatly among different centers. Our objective is to evaluate the TG-lowering effects of different therapies and their impact on clinical outcomes in HTG-AP patients with worrisome features. <b>Methods:</b> This is a multicenter, observational, prospective cohort study. A total of approximately 300 patients with HTG-AP with worrisome features are planned to be enrolled. The primary objective of the study is to evaluate the relationship between TG decline and the evolution of organ failure, and patients will be dichotomized depending on the rate of TG decline. The primary outcome is organ failure (OF) free days to 14 days after enrollment. Secondary outcomes include new-onset organ failure, new-onset multiple-organ failure (MOF), new-onset persistent organ failure (POF), new receipt of organ support, requirement of ICU admission, ICU free days to day 14, hospital free days to day 14, 60-day mortality, AP severity grade (Based on the Revised Atlanta Classification), and incidence of systemic and local complications. Generalized linear model (GLM), Fine and Gray competing risk regression, and propensity score matching will be used for statistical analysis. <b>Discussion:</b> Results of this study will reveal the current practice of TG-lowering therapy in HTG-AP and provide necessary data for future trials.

Item Type: Article
Uncontrolled Keywords: acute pancreatitis (AP), hypertriglyceridemia (HTG), TG-lowering therapy, organ failure free day, cohort study
Divisions: Faculty of Health and Life Sciences
Faculty of Health and Life Sciences > Institute of Population Health
Depositing User: Symplectic Admin
Date Deposited: 11 Jan 2022 14:19
Last Modified: 18 Jan 2023 21:16
DOI: 10.3389/fmed.2021.756337
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3146463